Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri, USA; Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri, USA.
Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri, USA; Division of Nuclear Medicine, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri, USA.
Clin Oncol (R Coll Radiol). 2021 May;33(5):300-306. doi: 10.1016/j.clon.2021.01.010. Epub 2021 Feb 11.
A complete metabolic response (CMR) on early post-treatment F-fluorodeoxyglucose positron emission tomography (FDG-PET) is a positive prognostic factor for cervical cancer patients treated with definitive chemoradiation, but long-term outcomes of this group of patients are unknown. Patterns of failure and risk subgroups are identified.
Patients who received curative-intent chemoradiation from 1998 to 2018 for International Federation of Gynecology and Obstetrics (FIGO) stage IB1-IVA cervical cancer and had a CMR on post-treatment FDG-PET within 5 months of treatment completion were included. Cox proportional hazards models determined factors associated with locoregional and distant failure. Kaplan-Meier estimates of freedom from any recurrence (FFR) of patient subgroups were compared with Log-rank tests.
There were 402 patients with a CMR after chemoradiation on FDG-PET. Initial T stage was T1 (38%)/T2 (40%)/T3 (20%)/T4 (2%); initial FDG-avid nodal status was no nodes (50%)/pelvic lymph nodes (40%)/pelvic and para-aortic lymph nodes (10%). After a median follow-up of 6 years, 109 (27%) recurred. The pattern of recurrence was locoregional (27%), distant (61%) or both (12%). No factors were associated with locoregional failure. Distant recurrence was more likely in patients with T3-4 lesions (hazard ratio = 2.4, 95% confidence interval 1.5-3.8) and involvement of pelvic (hazard ratio = 1.6, 95% confidence interval 1.0-2.7) or para-aortic lymph nodes (hazard ratio = 2.7, 95% confidence interval 1.4-5.0) at diagnosis. The 5-year FFR rates for T1-2 patients with no nodes, pelvic nodes alone or para-aortic nodes at diagnosis were 85, 76 and 62%, respectively (P = 0.04, none versus para-aortic nodes). The 5-year FFR for T3-4 patients with no nodes, pelvic nodes alone or para-aortic nodes at diagnosis were 68, 56 and 25%, respectively (P = 0.09, none versus para-aortic nodes).
T3-4 tumours and para-aortic nodal involvement at diagnosis are poor prognostic factors, even after a CMR following chemoradiation.
早期治疗后 F-氟代脱氧葡萄糖正电子发射断层扫描(FDG-PET)的完全代谢反应(CMR)是接受根治性放化疗的宫颈癌患者的阳性预后因素,但该组患者的长期结局尚不清楚。本研究旨在确定失败模式和风险亚组。
本研究纳入了 1998 年至 2018 年期间因国际妇产科联合会(FIGO)分期 IB1-IVA 宫颈癌接受根治性放化疗且在治疗完成后 5 个月内 FDG-PET 检查有 CMR 的患者。Cox 比例风险模型确定了与局部区域和远处失败相关的因素。采用 Kaplan-Meier 估计患者亚组的无任何复发(FFR)率,并进行 Log-rank 检验。
FDG-PET 检查显示 402 例患者在放化疗后有 CMR。初始 T 分期为 T1(38%)/T2(40%)/T3(20%)/T4(2%);初始 FDG 摄取淋巴结状态为无淋巴结(50%)/盆腔淋巴结(40%)/盆腔和主动脉旁淋巴结(10%)。中位随访 6 年后,109 例(27%)患者复发。复发模式为局部区域(27%)、远处(61%)或两者兼有(12%)。无任何因素与局部区域失败相关。T3-4 病变患者远处复发的风险更高(风险比=2.4,95%置信区间 1.5-3.8),且诊断时存在盆腔(风险比=1.6,95%置信区间 1.0-2.7)或主动脉旁淋巴结(风险比=2.7,95%置信区间 1.4-5.0)受累的患者远处复发风险更高。诊断时无淋巴结、仅盆腔淋巴结或主动脉旁淋巴结的 T1-2 患者的 5 年 FFR 率分别为 85%、76%和 62%(P=0.04,无 versus 主动脉旁淋巴结)。诊断时无淋巴结、仅盆腔淋巴结或主动脉旁淋巴结的 T3-4 患者的 5 年 FFR 率分别为 68%、56%和 25%(P=0.09,无 versus 主动脉旁淋巴结)。
即使在放化疗后 CMR 后,T3-4 肿瘤和主动脉旁淋巴结受累仍是不良预后因素。